阿达木单抗联合减量甲氨蝶呤对比最大耐受剂量甲氨蝶呤治疗类风湿关节炎患者(MIRACLE):一项随机、开放标签、非劣效性试验
MIRACLE研究纳入甲氨蝶呤初治、病程小于2年的类风湿关节炎患者,在甲氨蝶呤单药未达缓解后随机接受阿达木单抗联合减量或最大耐受剂量甲氨蝶呤。第48周SDAI缓解率减量组38% vs 最大耐受剂量组44%,校正风险差6.4%(90%CI -7.0至19.8),满足-15%非劣效界值。减量组不良事件有更少趋势(20% vs 35%,p=0.054)。
要点
- 阿达木单抗联合减量甲氨蝶呤在第48周SDAI缓解率非劣于联合最大耐受剂量甲氨蝶呤。
- 减量组不良事件发生率为20%,最大耐受剂量组为35%,组间差异未达统计学显著(p=0.054)。
- 研究期间无死亡,严重不良事件共14例,三组分别为6例、5例和3例。
核心结论
- MIRACLE研究显示,阿达木单抗联合减量甲氨蝶呤的疗效非劣于联合最大耐受剂量甲氨蝶呤,且安全性有更好趋势。
研究设计与样本
- 开放标签、随机对照非劣效性试验,在日本、韩国和中国台湾的24家二级或三级医院开展。
- 招募甲氨蝶呤初治、病程小于2年的类风湿关节炎患者,甲氨蝶呤口服并至第12周增至最大耐受剂量。
- 第24周未达SDAI缓解者按1:1随机接受阿达木单抗(40 mg,每两周一次)联合继续最大耐受剂量甲氨蝶呤或联合减量甲氨蝶呤。
- 主要终点为第48周SDAI缓解的非劣效性,在改良全分析集中评估,预设非劣效界值为-15%,基于双侧90%CI。
- 共筛查323例,入组300例,全分析集291例;随机分组为最大耐受剂量组68例和减量组66例。
主要发现
- 第48周SDAI缓解在减量组为25/66(38%),最大耐受剂量组为27/61(44%),校正风险差6.4%(90%CI -7.0至19.8),满足-15%非劣效界值。
- 第24周后不良事件在最大耐受剂量组有更频繁趋势:24例(35%) vs 减量组13例(20%),p=0.054。
- 第24周至48周共发生14例严重不良事件:甲氨蝶呤单药组6例、阿达木单抗联合最大耐受剂量甲氨蝶呤组5例、阿达木单抗联合减量甲氨蝶呤组3例;无死亡。
- 第24周时291例中105例(36%)达到缓解并继续甲氨蝶呤单药治疗至第48周;134例(46%)未达缓解并随机分组。
- 入组时平均年龄57.7岁(SD 15.2),女性217例(75%),男性74例(25%),均为亚洲 ethnicity;入组时平均SDAI为26.5(SD 12.4)。
关键数值与推荐
- 主要终点非劣效界值为-15%,基于双侧90%CI。
- 第48周SDAI缓解率减量组38% vs 最大耐受剂量组44%,校正风险差6.4%(90%CI -7.0至19.8)。
- 第24周后不良事件最大耐受剂量组35% vs 减量组20%,p=0.054。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of combination therapy with methotrexate and biological disease-modifying antirheumatic drugs is well established in the management of patients with rheumatoid arthritis; however, the optimal dose of methotrexate to administer with a tumour necrosis factor inhibitor remains unclear. We aimed to clarify the efficacy and safety of adalimumab combined with reduced methotrexate dose compared with the maximum tolerated methotrexate dose in patients with rheumatoid arthritis and an inadequate response to methotrexate monotherapy. METHODS: In this open-label, randomised controlled trial, we recruited methotrexate-naive patients with rheumatoid arthritis and a disease duration of less than 2 years across 24 secondary or tertiary care hospitals across Japan, South Korea, and Taiwan. At initiation, methotrexate was given orally and increased to the maximum tolerated dose by week 12. Patients who did not achieve remission on the basis of the Simplified Disease Activity Index (SDAI) at week 24 were randomly assigned (1:1) to receive adalimumab (40 mg biweekly) combined with a continued maximum tolerated dose of methotrexate or adalimumab combined with a reduced dose of methotrexate. The primary endpoint was non-inferiority of adalimumab plus reduced-dose methotrexate to adalimumab plus maximal-dose methotrexate based on SDAI remission at week 48, assessed in the modified full-analysis set with a pre-specified non-inferiority margin of -15%, based on a two-sided 90% CI. Adverse events were assessed in the safety analysis set. This trial is registered with ClinicalTrials.gov, NCT03505008 and has been completed. FINDINGS: From April 18, 2018, to June 2, 2020, from 323 patients screened, 300 were enrolled, and 291 patients were included in the full analysis set. The mean age was 57·7 years (SD 15·2), 217 (75%) were female, 74 (25%) were male, and all patients were of Asian ethnicity. The mean SDAI at study enrolment was 26·5 (SD 12·4). 52 patients discontinued the study before week 24 or at week 24 before randomisation. At week 24, 105 (36%) of 291 patients achieved remission and continued methotrexate monotherapy through week 48. 134 (46%) did not achieve remission at week 24 and were randomly assigned to receive adalimumab plus the maximum tolerated dose of methotrexate (n=68) or adalimumab plus reduced-dose methotrexate (n=66). Remission at week 48 was achieved in 25 (38%) of 66 and 27 (44%) of 61 patients, respectively, with an adjusted risk difference of 6·4% (90% CI -7·0 to 19·8), which met the non-inferiority margin of -15%. Adverse events after week 24 tended to be more frequent in the maximum tolerated dose group than in the reduced-dose group (24 [35%] vs 13 [20%], p=0·054). Between week 24 and 48, there were 14 serious adverse events (6 in the methotrexate monotherapy group, 5 in the adalimumab plus maximal-dose methotrexate, and 3 in the adalimumab plus reduced-dose methotrexate group), and no deaths. INTERPRETATION: The MIRACLE study showed that the efficacy of adalimumab combined with reduced methotrexate dose was not inferior to that with the maximum tolerated methotrexate dose, with a tendency to a better safety profile. FUNDING: Eisai.
引用
- Tamai H, Ikeda K, Miyamoto T, et al. Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial. Lancet Rheumatol. 2023. PMID: 38251524. doi:10.1016/S2665-9913(23)00070-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。